11988 El Camino Real
United States - Map
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The companys lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treatment of cardiac ischemic damage; and compounds for the treatment of diabetes and neurodegenerative diseases. Celladon Corporation was founded in 2000 and is headquartered in San Diego, California.
|Mr. Paul B. Cleveland J.D.,
Chief Exec. Officer and Director
|Ms. Elizabeth E. Reed J.D.,
VP, Gen. Counsel and Sec.
|Dr. Roger J. Hajjar Ph.D., M.D.,
Co-Founder and Scientific Advisor
|Mr. Andrew C. Jackson ,
Chief Financial Officer and Corp. Controller
|Mr. Fredrik Wiklund ,
VP of Corp. Devel. & Investor Relations
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|